Delaware will showcase its competitive advantages at the international BIO Convention in Philadelphia from June 3 to 6.
More than 18,000 venture capitalists, scientists, researchers and start-ups from 70 countries are expected to attend.
Eric Kmiec, Ph.D., head of Gene Editing at Christiana Care Health System and the pioneer of the CRISPR system is leading the gene editing section at the convention. In addition, 17 Delaware bioscience experts will serve as judges in the startup competition. Delaware will have an exhibit, which will include space to facilitate one-on-one meetings.
This year, Delaware is offering a tour of the state’s bioscience capabilities to conference attendees. The tour will stop in Wilmington, at the headquarters of Incyte, the biopharmaceutical research company. At Incyte, the group will hear a panel discussion featuring Incyte’s CEO, Hervé Hoppenot.
After Incyte, the tour will head to the University of Delaware’s STAR campus in Newark. The former Chrysler plant now hosts a variety of high-tech science and research companies and offers more than 10,000 square feet of wet labs. STAR (which stands for Science, Technology and Advanced Research) is home to the nation’s highest ranked physical therapy degree program as well as NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals). It will soon be home to Chemours Global Research as well.
“Delaware has the fourth highest number of employed PhDs working in science, engineering, and healthcare,” said Kurt Foreman, CEO of the Delaware Prosperity Partnership, the organization that manages statewide economic development for the state of Delaware. “Add to that its enviable location, low cost of doing business, and collaborative, business-friendly environment and you see why Delaware is becoming the go-to location for science and tech start-ups. Our seventh place ranking in the Milken Institute’s State Technology and Science Index underscored that Delaware is taking the lead in the bioscience field.”
“Delaware has a uniquely expansive array of bioscience businesses,” said Helen Stimson, CEO of the Delaware BioScience Association. “Unlikeother states, Delaware’s strength is its focus on innovation and its rich diversity of bioscience companies, including precision instrumentation, consumables, recombinant proteins, monoclonal antibodies, contract research organizations, and contract manufacturing organizations.”
For more information about the BIO Convention, Delaware’s participation, and the tour, visit www.choosedelaware.com/bio-convention